Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.47% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Icon
ICLR
$13B
| $404M | 0.31% |
2,347,059
+36,099
| +2% | +$5.57M |
|
|
ALXN
52
DELISTED
Alexion Pharmaceuticals
ALXN
| $404M | 0.31% |
3,731,144
+881,477
| +31% | +$94.3M |
|
|
MBT
53
DELISTED
Mobile TeleSystems Public Joint Stock Company American Depositary Shares (Each representing 2 Shares
MBT
| $402M | 0.31% |
39,612,969
+7,005,055
| +21% | +$64.1M |
|
54
Newmont
NEM
$98.5B
| $401M | 0.31% |
9,234,499
+1,966,320
| +27% | +$76.9M |
|
55
Seagate
STX
$185B
| $401M | 0.31% |
6,731,871
+2,494,526
| +59% | +$143M |
|
56
F5
FFIV
$23B
| $400M | 0.31% |
2,865,374
+569,200
| +25% | +$80.2M |
|
|
ABMD
57
DELISTED
Abiomed Inc
ABMD
| $396M | 0.3% |
2,323,023
+187,300
| +9% | +$34.7M |
|
58
Evergy
EVRG
$19.8B
| $390M | 0.3% |
5,986,756
-1,005,700
| -14% | -$64.1M |
|
59
Progressive
PGR
$125B
| $388M | 0.3% |
5,359,886
-414,910
| -7% | -$29.9M |
|
60
Southern Company
SO
$109B
| $384M | 0.3% |
6,028,863
-2,600,939
| -30% | -$161M |
|
61
Bausch Health
BHC
$1.67B
| $374M | 0.29% |
12,491,799
+7,429,396
| +147% | +$193M |
|
62
Teradyne
TER
$52.4B
| $368M | 0.28% |
5,401,749
-157,476
| -3% | -$10M |
|
|
HZNP
63
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $366M | 0.28% |
10,100,675
+750,100
| +8% | +$23M |
|
64
Consolidated Edison
ED
$41.1B
| $362M | 0.28% |
4,006,694
-273,706
| -6% | -$24.5M |
|
65
MarketAxess Holdings
MKTX
$4.19B
| $362M | 0.28% |
955,954
+237,744
| +33% | +$87.2M |
|
66
Ameren
AEE
$31B
| $351M | 0.27% |
4,571,208
-1,034,392
| -18% | -$78.6M |
|
67
Fox Class A
FOXA
$23.8B
| $347M | 0.27% |
9,349,489
+701,400
| +8% | +$24M |
|
68
NetEase
NTES
$79.2B
| $345M | 0.27% |
5,623,585
+3,492,085
| +164% | +$205M |
|
69
CSX Corp
CSX
$96B
| $341M | 0.26% |
14,142,675
+6,307,557
| +81% | +$149M |
|
70
NetApp
NTAP
$33.3B
| $340M | 0.26% |
5,464,940
-1,304,232
| -19% | -$76.1M |
|
71
Equity Lifestyle Properties
ELS
$12.6B
| $335M | 0.26% |
4,754,130
-327,472
| -6% | -$22.8M |
|
72
Public Storage
PSA
$60.5B
| $326M | 0.25% |
1,531,872
+11,915
| +0.8% | +$2.64M |
|
73
Vale
VALE
$62.9B
| $324M | 0.25% |
24,511,590
-7,169,700
| -23% | -$86.2M |
|
74
Colgate-Palmolive
CL
$73.6B
| $322M | 0.25% |
4,672,627
+109,900
| +2% | +$7.49M |
|
75
Exelixis
EXEL
$14B
| $316M | 0.24% |
17,953,926
+3,104,330
| +21% | +$52.6M |
|
Similar funds
Renaissance Technologies's Q4 2019 Portfolio in Review
As of Q4 2019, Renaissance Technologies held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Renaissance Technologies's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Renaissance Technologies added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Renaissance Technologies's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Renaissance Technologies fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Renaissance Technologies's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Renaissance Technologies opened 518 new positions and closed 443 in Q4 2019.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.